Introduction
Transfer and expression of multiple exogenous genes is an important requirement in a range of gene therapy protocols, including immune gene therapy of cancer. A large number of studies have shown that the expression of different combinations of therapeutic genes induces a much more efficient antitumour response than expression of single genes in tumour cells. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] However, the relative inefficiency of gene transfer procedures precludes the use of multiple vectors for the transfer and expression of different gene products. In principle, expression of several genes in a single vector can be achieved by inclusion in the vector of multiple expression cassettes each with its own independent promoter. A major disadvantage of this approach is the phenomenon of promoter interference, which is particularly acute in retroviral vectors. [12] [13] [14] As an alternative strategy, retroviral vectors containing internal ribosome entry sites (IRES) have enabled expression of polycistronic messengers. 15, 16 However, the instability of vectors with more than one IRES restricts the suitability of IRES vectors to expression of only two genes.
Here we describe a novel approach for the expression of multiple gene products from a single cistron encoding multiple products as a single fusion protein which is cleaved and processed after synthesis into its constituent, active, components. We have used furin, a ubiquitous endoprotease 17 localised to the Golgi apparatus 18 which is highly conserved among eukaryotic species. 19 Furin represents a general cellular endoprotease able to process a diverse group of precursor proteins secreted via the constitutive pathway with the consensus sequence Arg.X.Arg/Lys.Arg. [20] [21] [22] A number of studies have shown that incorporation of furin recognition sites into recombinant proteins results in the efficient secretion of these proteins from transduced cells. 23, 24 However, cleavage sites for furin or other endoproteases have not been previously utilised for the production of multiple gene products from chimeric fusion proteins (see Figure 1) . In the present study we have expressed different combinations of the cytokines IL-2, IL-4, IL-12 and the transmembrane protein B7.1, as fusion proteins which are separated by linkers encompassing furin target sequences. The secretion and biological activity of IL-2, IL-4 and IL-12 has been confirmed by ELISA, CTLL and lymphoblast proliferation assays. The expression and biological activity of B7.1 has been confirmed by FACS analysis and its ability to costimulate the production of IL-2 by the human Jurkat T cell line and freshly isolated mouse splenocytes.
Results

Vector construction
Two retroviral vectors were constructed in which the coding sequences for B7.1 and IL-2 were cloned in-frame with a furin recognition site between the two cDNAs (Figure 2a and b) . In both vectors the IL-2 coding sequence is followed by either the coding sequence for mature B7.1, lacking its signal peptide (pWZLIL2/B7M, Figure 2a ), or the full coding sequence of B7.1, containing its signal peptide (pWZLIL2/B7F, Figure 2b ). The IL-2/B7.1 sequence is followed by the encephalomyocarditis virus (ECMV) internal ribosome entry site (IRES), which allows the translation of the blasticidin acetyl transferase (Blast), conferring resistance to blasticidin S. In both vectors the IL-2 signal peptide is responsible for the transport of the chimeric IL-2/B7.1 protein into the endoplasmic reticulum (ER). The chimeric protein is transported to the Golgi with the B7.1 transmembrane domain anchoring the protein to the membrane. This will allow the furin-mediated cleavage of the chimeric protein in the Golgi, resulting in generation of a membrane bound B7.1 and secreted IL-2 (see Figure 1) .
In a control vector, pWZLB7/IL2M (Figure 2c ), the relative positions of the IL-2 and B7.1 cDNA were reversed. In this vector the signal peptide of B7.1, instead of IL-2, is used for transport into the ER. In this configuration the presence of the B7.1 transmembrane region prevents entry of the C-terminal portion of the fusion protein (containing the B7.1 cytoplasmic region, furin cleavage site and mature IL-2) into the lumen of the ER. Therefore, cleavage of the furin site cannot take place because the furin recognition site remains outside the Golgi.
To investigate the general applicability of this approach, the same strategy was used to construct fusion proteins encompassing different combinations of cDNAs. The vector pWZLIL4/B7M encodes a chimeric IL-4/B7.1 (Figure 2d ), pWZLIL4/IL2M encodes IL4/IL-2 ( Figure  2e ), and pcDNAIL12 encodes the p40 and p35 subunits of IL-12 (Figure 2f ), in each case with an in-frame furin site between the two coding sequences. In order to examine the suitability of this strategy for expression of multiple proteins a vector encoding three proteins was constructed (pcDNAIL12/IL2). In this construct the p40 and p35 subunits of IL-12 are separated by IL-2 and two furin cleavage sites (Figure 2g ).
The plasmids a to e were introduced into retroviral packaging cells and following selection for blasticidin S resistance both amphotropic and ecotropic retrovirus producer cell lines were isolated. These retroviral vectors were used for the transduction of target cells and analysis of expression and functional activity of the encoded proteins. The plasmids f and g were transfected into COS7 cells and analysed for expression and functional activity. Figure 2b , pWZLIL2/B7) there was a 10-fold reduction in cytokine release ( Table 1 ). The precise mechanism for this reduced production of cytokine is not clear but it is probably due to interference with either insertion of the fusion protein into the ER, or its subsequent furin cleavage in the Golgi. However, the generation of a membrane-anchored B7.1 and a secreted cytokine from cells infected with these vectors is clearly dependent on the presence of the furin cleavage site. If the furin cleavage site is destroyed (by removal of the Arg/Lys amino acid in position three of the furin cleavage site) the chimeric protein is secreted without cleavage (data not shown). Similarly, if the furin site is placed in a configuration preventing its entry into the lumen of the ER there is no cytokine release. This is clearly demonstrated in cells transduced with pWZLB7/IL2M (Figure 2c) , in which the furin recognition site is linked to the cytoplasmic domain of the B7.1. In this configuration the furin cleavage site remains in the cytoplasm, does not enter the lumen of ER, and gains no access to furin in the Golgi. However, despite lack of IL-2 expression (Table 1) there is clear evidence of B7.1 expression on the cell surface as determined by FACS analysis (Figure 3a) .
Biological activity of the fusion gene products
To determine the biological activity of the secreted cytokines, their effect on proliferation ( 3 H-thymidine incorporation) of the cytokine-dependent CTLL cells was measured.
Cells transduced with the vector pWZLIL2/B7M produced significantly more T cell growth factor (TCGF) than those transduced with pWZLIL2/B7F; this is consistent with the ELISA-based measurements of the cytokine levels ( Table 1) . Addition of a neutralising anti-IL-2 antibody, but not an irrelevant antibody, could block the stimulation of CTLL proliferation (Figure 3b) . Similarly, the IL-2 and IL-4 produced by cells transduced with pWZLIL4/B7M, pWZLIL4/ IL2M and pcDNAIL12/IL2 were found to be biologically active (data not shown). The bioactivity of IL-12 produced by COS7 cells transduced with either pcDNA IL12 or pcDNAIL12/IL2 was analysed on activated human T cells ( Table 1) .
The bioactivity of B7.1 was analysed by a Jurkat T cell costimulation assay. The coculture of Jurkat cells with the pWZLIL2/B7M transduced cells in the presence of PHA-P induced increased levels of IL-2 secretion (Figure 3c ). The costimulation of Jurkat cells was B7.1 dependent, as shown by the ability of an anti-B7.1 antibody (clone 5B5) to block the secretion of IL-2. The failure of an anti-IL-2R antibody (clone 33B.1) to block the costimulation confirms the dependence of this activation on B7.1, and not IL-2. This was further confirmed with freshly prepared mouse splenocytes which also produce IL-2 in response to B7.1 costimulation and CD3 activation (data not shown).
Concomitant expression of encoded proteins in clonal populations of cells
To investigate the expression of both B7.1 and IL-2 in different cells, a panel of mouse and human cell lines were infected with the fusagene vectors and expression of the encoded proteins was assessed. 32Dp210 murine myeloma, K562 human erythroid leukaemia, A431 human cervical carcinoma and three human ovarian cancer cell lines OIB, SKOV-3 and OVCA-432 were infected with the pWZLIL2/B7M fusion vector and individual clones were selected and expanded. These clones were subsequently assessed for the cell surface expression of B7.1 and the secretion of IL-2 into the culture medium. In 107 of the 108 clones tested, surface expression of B7.1 was detectable by FACS analysis, and concomitant secretion of IL-2 could be detected in the culture medium by ELISA ( Table 2) .
Efficiency of furin cleavage of fusion proteins
In order to investigate the efficiency of protein cleavage, the presence of uncleaved IL-2 on the surface of clonal populations of cells was examined. In different human cell lines transduced with pWZLIL2/B7M and expressing up to 7.3 ng/10 6 cells/24 h there is a small but detectable level of IL-2 on the cell surface (see Figure 4 , clone 9). In contrast, in cells expressing three-fold higher levels of secreted IL-2 there is much more uncleaved IL-2 on the cell surface, indicating the saturation of the furinmediated cleavage (see Figure 4 , clone 10). Increased expression of furin, as a result of transduction with a furin expression vector, enhances the efficiency of cleavage of the fusion proteins as indicated by reduction of the surface IL-2 to background levels, with a concomitant increase in the secreted IL-2 from 21.6 to 32.8 ng/10 6 /24 h (Figure 4 , clone 10/furin).
For further quantification of the efficiency of cleavage, the levels of cleaved and total cytokines were measured in the culture medium of cells infected with vectors encoding IL-2/IL-4 ( Figure 2e ). In these assays, antibodies to one cytokine (eg IL-2) were used for capture, and antibodies to the other cytokine for quantification. These studies demonstrate that even in mouse fibroblasts expressing over 35 ng of IL-2 and IL-4/10 6 cells/24 h, over 50% of the products are cleaved. The furin cleavage of the fusion proteins was further studied by Western blot analysis of proteins secreted into the supernatant of mouse fibroblasts transduced with pWZLIL4/IL2M. In cells producing 18 and 20 ng/10 6 cells/24 h of IL-2 and IL-4, respectively (see Table 1 ), approximately 50% of the fusion protein is cleaved (data not shown).
Discussion
The expression of multiple gene products is a requirement in a number of biological applications. However, this cannot be easily achieved with the presently available vectors. Furthermore, none of the current methods allow the co-ordinated expression of the encoded genes, and are therefore unsuitable for situations in which equimolar amounts of two or more gene products are required. This is a particularly important consideration for gene transfer studies in which the desired biological activity is the product of heterogeneous subunits (eg expression of the p40 subunit in molar excess to the p35 subunit of IL-12 results in inhibition of its immune stimulatory activity). 25, 26 The use of endoprotease cleavage sites enables the expression of a monocistronic transcript that is translated into a chimeric fusion product which is then processed by endoprotease cleavage to its constituent components. Therefore, the molar ratio of the protein products will be determined by the frequency of their representation in the vector. If the vector contains one IL-2 and one IL-4 coding sequence, the two cytokines will be expressed in equimolar ratio (see Table 1 ); if there are two IL-2 and one IL-4 coding sequences, the two cytokines will be expressed in the corresponding 2:1 molar ratio. Furthermore, the fact that several expression vectors (including plasmid, retroviral as well as adenoviral vectors -not shown), each containing different combinations of genes, all resulted in production of biologically active proteins indicates the broad applicability of this approach.
Two previous studies have made use of furin cleavage In each of the cell lines the background level of secreted IL-2 in control untransduced cells was Ͻ0.01 ng/10 6 cells/24 h and less than 8 for surface expressed B7.1. MFI, mean fluorescent intensity.
Figure 4 FACS analysis of membrane-bound B7.1 and IL-2 on the surface of A431 cells transduced with pWZLIL2/B7M either in the absence or presence of exogenous furin (pCMVmFur). The amounts of IL-2 secreted into the medium of the different cell lines were measured by ELISA and are indicated in each of the FACS profiles of the membrane-bound IL-2.
sites, not for the production of multiple proteins from a single cistron, but for the secretion of proteins that are normally intracellular, 23 or for the production of peptides that are normally secreted, but only by specific cell types. 27 In the first study, an antibody Fc fragment was fused via a furin cleavage site to the pro-calcitonin signal peptide, resulting in the secretion of the Fc fragment. 23 In the second study, angiotensin II was fused via the furin recognition site to a portion of prorenin containing its signal peptide, thus enabling the secretion of angiotensin II by cells which lack the complete modification system needed for the production of the mature peptide. 27 
Gene Therapy
The variation in the level of IL-2 produced in different cell lines is likely to be a reflection of the variation in the endogenous furin levels. The level of IL-2 production by 32Dp210 cells is much lower than that observed in K562, OIB, A431, SKOV-3 and OVCA-432 cells. This is corroborated by the presence of FACS detectable IL-2 on the surface of the cells. The presence of IL-2 on the cell surface is not due to nonspecific binding of IL-2 to the cells because when IL-2 is produced by cells transduced with monocistronic IL-2 vectors no surface expression of IL-2 is detectable (results not shown). The levels of secreted IL-2 were generally higher in the human tumour cell lines than in the murine lymphoma or fibroblast cell lines. This could be due to increased transcription efficiency or stability of furin in these human tumour cells. This reduced level or inefficiency of furin-mediated processing has also been observed in COS cells. Only a small fraction of pro von Willebrand factor 28 and rat proinsulin I, 29 both of which are normally processed by furin into their biologically active products, were produced in these cells. Cotransfection of COS cells with vectors encoding furin resulted in increased secretion of protein in both studies. 28, 29 Therefore, in cells with low endogenous levels of furin, introduction of furin expression vectors, or inclusion of furin in the fusagene vector, should result in increased cleavage. Furthermore, changes to the furin cleavage site itself could improve the cleavage efficiency. In Chinese hamster ovary cells the amino acid sequence Arg-X-Lys-Arg enables 50% cleavage of the precursor protein, whilst Arg-X-Arg-Arg results in only 30% cleavage. 30 We are currently analysing the influence of different amino acids in position 2 and the effect of tandem furin target sites on the efficiency of cleavage by furin in human cell lines.
However, even without co-expression of furin and without the use of these modified furin cleavage sites, the endogenous levels of furin in human tumour cell lines are sufficient for secretion of high levels of IL-2 (eg 85 ng/10 6 cells/24 h in K562 cells, Table 1 ). Finally, the use of tissue-specific endoprotease cleavage sites, rather than the ubiquitously expressed furin, will introduce a further level of specificity, resulting in production of the desired biologically active components in specific tissues. This would introduce a further level of targeting (in addition to tissue-specific delivery and transcription) and is likely to be a particularly attractive strategy for the delivery of cytotoxic compounds and drug convertase genes to tumour cells.
Materials and methods
Plasmids
The coding sequences for either full-length B7.1 or mature B7.1 (without the signal peptide), IL-2, IL-4 and IL-12 p35 or p40 were generated by PCR. The primers used incorporated partial furin recognition sites, suitable restriction sites and the gene-specific sequences. The antisense primers removed the stop codon from the 5′ cDNA and the sense primers removed the signal peptides from the cDNA in the 3′ position. After digestion and ligation the constructs contained an in-frame fusion with a furin cleavage site between the cDNAs. For example, the PCRgenerated coding sequences of B7.1 and IL-2 were digested and ligated together in-frame with an intervening furin cleavage site which contained at each end two additional glycine residues to make the cleavage site spatially more accessible. This sequence (GGC-GGC-AGG-GGT-CGA-CGC-GGC-GGC) contained a SalI site (indicated in bold), and encodes Gly.Gly.Arg.Gly. Arg.Arg.Gly.Gly. These constructs were then cloned into expression vectors. All constructs were verified by sequencing. The murine furin cDNA cloned into pRcCMV (Invitrogen, Groningen, The Netherlands) was a kind gift from Dr K Nakayama (University of Tsukuba, Ibaraki, Japan). 31 Production of the fusagene retroviral vectors Retroviral vectors were transfected into the ecotropic retroviral packaging cell line (GP+E-86), the culture supernatant of which, after selection in 4-8 g/ml blasticidin S, was used to infect the amphotropic packaging cell line (GP+env-AM12) cells. The culture supernatant of individual clones of GP+envAM12 cells was used to infect different target cells essentially as previously described. 2 The pcDNA expression vectors were transfected into COS7 cells and 48 h after transfection the cells were counted and 5 × 10 5 cells were plated. After 24 h the supernatant was harvested and ELISA, CTLL and lymphocyte proliferation assays were performed.
Analysis of cytokine production and B7.1 expression Cytokine production: The level of IL-2 and IL-4 was measured either by ELISA, using the antibodies secreted by the clones JES6-1A12 and 11B11 for the capture and detection of IL-2, respectively; or JES6-5H4 and BVD6-24G2 (Pharmingen, San Diego, CA, USA) for the capture and detection of IL-4. The biological activity of these cytokines was assessed by 3 H-thymidine incorporation by CTLL cells. This assay was performed in the presence of 1 g/ml of either an irrelevant antibody (clarified ascites of clone UPC10, mouse IgG2a) or neutralising antibodies to either IL-2 (purified, clone 5334.2, mouse IgG2a; R&D Systems, Minneapolis, MN, USA), or IL-4 (11B11). IL-12 biological activity was measured by lymphoblast proliferation assays. 32 Membrane-bound IL-2 was measured by flow cytometry, using an anti-IL-2 antibody (clone 5355.111; R&D Systems) and detected with FITC-conjugated goat anti-mouse IgG (Dako, High Wycombe, UK).
B7.1 expression and activity: Expression of B7.1 was measured by flow cytometry, using the counter-receptor fusion protein CTLA-4Ig and detected with FITC-conjugated goat anti-human IgG (Sigma, Poole, UK). The CTLA-4Ig was a gift from Dr Christian Dö hring, Basel Institute for Immunology, Basel, Switzerland. 33 The biological activity of the hB7.1 was confirmed by a CD28-mediated T cell costimulation assay. The hB7.1 expressing cells were cocultured in the presence or absence of 1 g/ml of either an irrelevant isotype matched monoclonal antibody (clone UPC10, mouse IgG2a; Sigma), a monoclonal anti-CD25 (clone 33B.1 rat IgG2a; Immunotech) or an anti-B7.1 monoclonal antibody (clone 5B5 mouse IgG2a, Innogenetics, High Wycombe, UK) with Jurkat T cells cultured with 2-4 g/ml PHA-P (to activate the CD3 complex). IL-2 secretion by the activated Jurkat cells was assessed as described above.
